title: Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy.
abstract: IMRT and helical tomotherapy for head and neck cancer (HNC) treatment are associated with higher doses to certain non-target tissues than traditional static beam techniques. We hypothesized that this may lead to higher acute mucosal and hematologic toxicities. This analysis was limited to 178 patients receiving ≥60 Gy with concurrent weekly cisplatin. Radiation delivery used 3D-CRT in 41 patients (23%), conventional IMRT in 56 patients (31%), and helical tomotherapy in 81 patients (46%). Acute mucositis rates, weekly hematologic parameters, and ability to deliver planned chemotherapy cycles were examined for each patient during their course of chemoradiotherapy. Analysis showed patients were well balanced with regard to sex, age, and stage. Treatment time, as assessed by delivered monitor units, varied significantly between the 3D-CRT (median = 502), IMRT (median = 1087), and tomotherapy (median = 6757) cohorts. Acute mucositis grades did not significantly differ between the three subsets. Through six weeks of chemoradiotherapy, the median decline in hemoglobin was 15.6%, the median decline in platelets was 30.6%, and the median decline in leukocytes was 51.5%, but these drops were not significantly different between treatment cohorts. Chemotherapy was discontinued or held secondary to hematologic toxicity in 12% of 3D-CRT patients, 5% of IMRT patients and 15% of tomotherapy patients (p = 0.14). In conclusion, HNC patients undergoing high dose radiation with concurrent weekly cisplatin chemotherapy, the longer beam-on times and larger volumes of low-to-moderate radiation doses to non-target tissues associated with modern IMRT delivery techniques do not appear to result in increased acute hematologic or mucosal toxicities.
authors.affiliation: Department of Human Oncology, University of Wisconsin Carbone Cancer Center K4/B100 CSC, 600 Highland Avenue, Madison, WI 53792. kruser@humonc.wisc.edu.
authors.forename: Tim J
authors.initials: TJ
authors.lastname: Kruser
authors.forename: Stephanie R
authors.initials: SR
authors.lastname: Rice
authors.forename: Kevin P
authors.initials: KP
authors.lastname: Cleary
authors.forename: Heather M
authors.initials: HM
authors.lastname: Geye
authors.forename: Wolfgang A
authors.initials: WA
authors.lastname: Tome
authors.forename: Paul M
authors.initials: PM
authors.lastname: Harari
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Kozak
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006402:Hematologic Diseases / Q000209:etiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology*; D010976:Platelet Count; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects* / Q000379:methods; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D002945:Cisplatin
references.citation: Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1179-84
references.pmid: 21601995
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1185-91
references.pmid: 22270171
references.citation: Phys Med Biol. 2006 Jul 7;51(13):R427-53
references.pmid: 16790916
references.citation: Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16
references.pmid: 11240231
references.citation: Head Neck. 2010 May;32(5):599-606
references.pmid: 19757422
references.citation: Technol Cancer Res Treat. 2013 Apr;12(2):123-30
references.pmid: 23098281
references.citation: Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):931-8
references.pmid: 17011465
references.citation: Radiother Oncol. 2009 Jul;92(1):4-14
references.pmid: 19446902
references.citation: Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39
references.pmid: 7713791
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):893-9
references.pmid: 21477946
references.citation: Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):747-55
references.pmid: 18455324
references.citation: Lancet Oncol. 2011 Feb;12(2):127-36
references.pmid: 21236730
references.citation: Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e101-7
references.pmid: 22342095
references.citation: Radiother Oncol. 2001 Oct;61(1):33-44
references.pmid: 11578726
references.citation: N Engl J Med. 2004 May 6;350(19):1937-44
references.pmid: 15128893
references.citation: Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1187-95
references.pmid: 19251090
references.citation: Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):235-42
references.pmid: 22104358
references.citation: N Engl J Med. 2004 May 6;350(19):1945-52
references.pmid: 15128894
references.citation: Lancet. 2000 Mar 18;355(9208):949-55
references.pmid: 10768432